𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease

✍ Scribed by Craig D. McColl; Katrina A. Reardon; Mark Shiff; Peter A. Kempster


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
935 KB
Volume
17
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Thirty-four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disease progresses. Objective measurements of the motor response to levodopa test-doses were made at approximately three yearly intervals. Motor fluctuations developed in 58% of the patient group after a mean treatment period of 35 months. Dyskinesia developed in parallel with fluctuations but appeared on average 7 months before symptomatic wearing-off effects of levodopa doses. The patients with motor fluctuations had significantly better responses to levodopa. By contrast, nonfluctuators were more prone to develop increasing midline motor disability affecting speech, gait and balance. Comparison of test-dose and pretreatment scores suggested that a substantial long-duration response to levodopa remains after many years of treatment, and that lateralized motor deficits show a stronger long duration response than midline ones. Motor fluctuations are a consequence of disease progression but their early development is, on balance, associated with better long-term functional ability because these patients have the greater capacity to respond to pharmacological treatment.


πŸ“œ SIMILAR VOLUMES


Longitudinal study of the motor response
✍ Benjamin G. Clissold; Craig D. McColl; Katrina R. Reardon; Mark Shiff; Peter A. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 132 KB πŸ‘ 1 views

## Abstract In this prospective study of 34 patients with Parkinson's disease, measurements of the short duration levodopa motor response have been performed in defined __off__ states at 3 yearly intervals over a mean period of 11.4 years from the point of commencement of levodopa treatment. Twenty

Longitudinal study of the levodopa motor
✍ Jane E. Alty; Benjamin G. Clissold; Craig D. McColl; Katrina A. Reardon; Mark Sh πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 1 views

## Abstract In this prospective study of 34 patients with Parkinson's disease (PD), measurements of the short duration levodopa motor response have been performed every 3 years in defined __off__ states. The mean time from initiation of levodopa treatment was 14.8 years, and 17 patients survived to

Study of istradefylline in patients with
✍ Robert A. Hauser; Lisa M. Shulman; Joel M. Trugman; John W. Roberts; Akihisa Mor πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 150 KB πŸ‘ 1 views

## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW‐6002) is an adenosine A~2A~ receptor a

Gait analysis in patients with Parkinson
✍ John D. O'Sullivan; Catherine M. Said; Louise C. Dillon; Marion Hoffman; Dr. And πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 727 KB

## Abstract Although clinical rating scales and simple timed tests of motor function are widely used to assess motor response to therapy, gait analysis may provide an alternative measure of this response. We studied 15 patients with PD complicated by motor fluctuations, first to determine changes i

Melevodopa/carbidopa effervescent formul
✍ Fabrizio Stocchi; Mario Zappia; Valentina Dall'Armi; Jaime Kulisevsky; Paolo Lam πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 188 KB

## Abstract Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double‐blind, double‐dummy, controlled parallel group study, whic